Angiogenesis inhibitors in gastric and gastroesophageal junction cancer
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Angiogenesis inhibitors in gastric and gastroesophageal junction cancer
Authors
Keywords
Gastric cancer, VEGF, Bevacizumab, Ramucirumab
Journal
Gastric Cancer
Volume 19, Issue 1, Pages 31-41
Publisher
Springer Nature
Online
2015-09-01
DOI
10.1007/s10120-015-0537-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 615ORANDOMIZED PHASE II STUDY OF CAPECITABINE AND CISPLATIN WITH OR WITHOUT SORAFENIB IN PATIENTS WITH METASTATIC GASTRIC CANCER: STARGATE STUDY
- (2017) Y. Kang et al. ANNALS OF ONCOLOGY
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experience
- (2015) Roberto Petrioli et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- c-Met targeting in advanced gastric cancer: An open challenge
- (2015) Luigi Marano et al. CANCER LETTERS
- Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight
- (2015) Giuseppe Aprile et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
- (2015) Razvan Cristescu et al. NATURE MEDICINE
- Unmet needs and challenges in gastric cancer: The way forward
- (2014) Florian Lordick et al. CANCER TREATMENT REVIEWS
- Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)
- (2014) Lin Shen et al. Gastric Cancer
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
- (2014) Hansjochen Wilke et al. LANCET ONCOLOGY
- Comprehensive molecular characterization of gastric adenocarcinoma
- (2014) Adam J. Bass et al. NATURE
- Over the RAINBOW—renaissance in antiangiogenesis
- (2014) Florian Lordick Nature Reviews Clinical Oncology
- HIF-1 Alpha Overexpression Correlates with Poor Overall Survival and Disease-Free Survival in Gastric Cancer Patients Post-Gastrectomy
- (2014) Li Chen et al. PLoS One
- HER2 therapies and gastric cancer: A step forward
- (2014) Ramon Andrade de Mello WORLD JOURNAL OF GASTROENTEROLOGY
- Clinical management of advanced gastric cancer: The role of new molecular drugs
- (2014) Ferdinando De Vita WORLD JOURNAL OF GASTROENTEROLOGY
- Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A gemcad study
- (2013) M. Martin-Richard et al. INVESTIGATIONAL NEW DRUGS
- Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study
- (2013) Atsushi Ohtsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of Statins and the Risk of Death in Patients With Prostate Cancer
- (2013) Oriana Yu et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- (2013) Charles S Fuchs et al. LANCET
- A Phase II Study of Capecitabine, Oxaliplatin, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas
- (2013) H. E. Uronis et al. ONCOLOGIST
- Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report
- (2012) A. F. C. Okines et al. ANNALS OF ONCOLOGY
- Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis
- (2012) Y. Y. Janjigian et al. ANNALS OF ONCOLOGY
- A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets
- (2012) Niantao Deng et al. GUT
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer
- (2011) Taroh Satoh et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo
- (2011) Shu Tian et al. CANCER SCIENCE
- Basic and Therapeutic Aspects of Angiogenesis
- (2011) Michael Potente et al. CELL
- An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer
- (2011) M. Moehler et al. EUROPEAN JOURNAL OF CANCER
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
- (2011) Atsushi Ohtsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor angiogenesis: molecular pathways and therapeutic targets
- (2011) Sara M Weis et al. NATURE MEDICINE
- A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers
- (2010) B. F. El-Rayes et al. ANNALS OF ONCOLOGY
- Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies
- (2010) Jin Li et al. BMC CANCER
- Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-β phosphorylation, and microvessel density in gastric cancer
- (2010) Shioto Suzuki et al. BMC CANCER
- Phase II study of sunitinib as second-line treatment for advanced gastric cancer
- (2010) Yung-Jue Bang et al. INVESTIGATIONAL NEW DRUGS
- Epirubicin, Oxaliplatin, and Capecitabine With or Without Panitumumab for Advanced Esophagogastric Cancer: Dose-Finding Study for the Prospective Multicenter, Randomized, Phase II/III REAL-3 Trial
- (2010) Alicia F.C. Okines et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
- (2010) Jennifer L. Spratlin et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Sorafenib in Combination With Docetaxel and Cisplatin in the Treatment of Metastatic or Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: ECOG 5203
- (2010) Weijing Sun et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter Phase II Study of Everolimus in Patients With Previously Treated Metastatic Gastric Cancer
- (2010) Toshihiko Doi et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil With Bevacizumab in Patients With Metastatic Gastroesophageal Adenocarcinoma
- (2010) Manish A. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Current status of cediranib: the rapid development of a novel anti-angiogenic therapy
- (2009) Colin R Lindsay et al. Future Oncology
- Clinicopathologic significance of HIF-1α, p53, and VEGF expression and preoperative serum VEGF level in gastric cancer
- (2008) Sung Yong Oh et al. BMC CANCER
- Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer
- (2008) S Rao et al. BRITISH JOURNAL OF CANCER
- Locally Advanced and Metastatic Gastric Cancer
- (2008) Kathryn Field et al. DRUGS
- Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
- (2008) Scott M. Wilhelm et al. MOLECULAR CANCER THERAPEUTICS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now